{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:21:21Z","timestamp":1787167281760,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":114,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319221076","type":"print"},{"value":"9783319221083","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/5584_2016_124","type":"book-chapter","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T10:14:29Z","timestamp":1472811269000},"page":"325-350","source":"Crossref","is-referenced-by-count":9,"title":["Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs"],"prefix":"10.1007","author":[{"given":"Morten","family":"W\u00fcrtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"124_CR1","unstructured":"FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Food and Drug Administration, 2010. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203888.htm . Accessed 23 Apr 2015"},{"key":"124_CR2","unstructured":"Public statement on possible interaction between clopidogrel and proton pump inhibitors. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/11\/WC500014409.pdf . Accessed 23 Apr 2015"},{"key":"124_CR3","unstructured":"Public statement: interaction between clopidogrel and proton-pump inhibitors CHMP updates warning for clopidogrel-containing medicines. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2010\/03\/WC500076346.pdf . Accessed 23 Apr 2015"},{"issue":"37","key":"124_CR4","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P et al (2014) 2014 ESC\/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541\u20132619","journal-title":"Eur Heart J"},{"issue":"24","key":"124_CR5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK et al (2014) 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64(24):e139\u2013e228","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"124_CR6","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.2174\/138161212803251925","volume":"18","author":"M Wurtz","year":"2012","unstructured":"Wurtz M, Grove EL (2012) Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 18(33):5344\u20135361","journal-title":"Curr Pharm Des"},{"issue":"10","key":"124_CR7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","volume":"30","author":"K Johnell","year":"2007","unstructured":"Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30(10):911\u2013918","journal-title":"Drug Saf"},{"issue":"9","key":"124_CR8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","volume":"29","author":"H Blume","year":"2006","unstructured":"Blume H, Donath F et al (2006) Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29(9):769\u2013784","journal-title":"Drug Saf"},{"issue":"9214","key":"124_CR9","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(00)02175-9","volume":"355","author":"JN George","year":"2000","unstructured":"George JN (2000) Platelets. Lancet 355(9214):1531\u20131539","journal-title":"Lancet"},{"issue":"22","key":"124_CR10","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodriguez LA et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353(22):2373\u20132383","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"124_CR11","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","volume":"126","author":"C Patrono","year":"2004","unstructured":"Patrono C, Coller B et al (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):234S\u2013264S","journal-title":"Chest"},{"issue":"4","key":"124_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/01.CIR.96.4.1109","volume":"96","author":"F Cipollone","year":"1997","unstructured":"Cipollone F, Patrignani P et al (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96(4):1109\u20131116","journal-title":"Circulation"},{"issue":"8","key":"124_CR13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.113.004480","volume":"129","author":"C Patrono","year":"2014","unstructured":"Patrono C, Baigent C (2014) Nonsteroidal anti-inflammatory drugs and the heart. Circulation 129(8):907\u2013916","journal-title":"Circulation"},{"issue":"8607","key":"124_CR14","first-page":"349","volume":"2","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607):349\u2013360","journal-title":"Lancet"},{"issue":"7141","key":"124_CR15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","volume":"316","author":"C Baigent","year":"1998","unstructured":"Baigent C, Collins R et al (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316(7141):1337\u20131343","journal-title":"BMJ"},{"issue":"7","key":"124_CR16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","volume":"309","author":"HD Lewis Jr","year":"1983","unstructured":"Lewis HD Jr, Davis JW et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309(7):396\u2013403","journal-title":"N Engl J Med"},{"issue":"22","key":"124_CR17","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","volume":"313","author":"JA Cairns","year":"1985","unstructured":"Cairns JA, Gent M et al (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313(22):1369\u20131375","journal-title":"N Engl J Med"},{"issue":"17","key":"124_CR18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"P Theroux","year":"1988","unstructured":"Theroux P, Ouimet H et al (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319(17):1105\u20131111","journal-title":"N Engl J Med"},{"issue":"8719","key":"124_CR19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","volume":"336","author":"The RISC Group","year":"1990","unstructured":"The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719):827\u2013830","journal-title":"Lancet"},{"issue":"9678","key":"124_CR20","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849\u20131860","journal-title":"Lancet"},{"issue":"1","key":"124_CR21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui M, Nishiya Y et al (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92\u201399","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"124_CR22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2133\/dmpk.23.412","volume":"23","author":"K Hagihara","year":"2008","unstructured":"Hagihara K, Nishiya Y et al (2008) Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 23(6):412\u2013420","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"124_CR23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494\u2013502","journal-title":"N Engl J Med"},{"issue":"12","key":"124_CR24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179\u20131189","journal-title":"N Engl J Med"},{"issue":"9497","key":"124_CR25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1607\u20131621","journal-title":"Lancet"},{"key":"124_CR26","unstructured":"IMS (2010) Global prescription sales information. Top 20 global products, 2010. Available from: http:\/\/www.imshealth.com\/deployedfiles\/ims\/Global\/Content\/Corporate\/Press%20Room\/Top-line%20Market%20Data\/2010%20Top-line%20Market%20Data\/Top_20_Global_Products.pdf . Accessed 23 April 2015"},{"issue":"20","key":"124_CR27","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"11","key":"124_CR28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057","journal-title":"N Engl J Med"},{"issue":"7571","key":"124_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","volume":"333","author":"J Hallas","year":"2006","unstructured":"Hallas J, Dall M et al (2006) Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333(7571):726","journal-title":"BMJ"},{"issue":"2","key":"124_CR30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11606-012-2208-0","volume":"28","author":"EL Grove","year":"2012","unstructured":"Grove EL, Wurtz M et al (2012) Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 28(2):216\u2013222","journal-title":"J Gen Intern Med"},{"issue":"14","key":"124_CR31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jacc.2009.07.019","volume":"54","author":"E Nikolsky","year":"2009","unstructured":"Nikolsky E, Stone GW et al (2009) Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 54(14):1293\u20131302","journal-title":"J Am Coll Cardiol"},{"issue":"7270","key":"124_CR32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","volume":"321","author":"S Derry","year":"2000","unstructured":"Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321(7270):1183\u20131187","journal-title":"BMJ"},{"issue":"18","key":"124_CR33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","volume":"118","author":"DL Bhatt","year":"2008","unstructured":"Bhatt DL, Scheiman J et al (2008) ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118(18):1894\u20131909","journal-title":"Circulation"},{"issue":"4","key":"124_CR34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","volume":"4","author":"US Tantry","year":"2011","unstructured":"Tantry US, Kereiakes DJ et al (2011) Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 4(4):365\u2013380","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"124_CR35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","volume":"34","author":"S Agewall","year":"2013","unstructured":"Agewall S, Cattaneo M et al (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34(23):1708\u20131713b","journal-title":"Eur Heart J"},{"issue":"9684","key":"124_CR36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(09)61246-0","volume":"374","author":"AS Taha","year":"2009","unstructured":"Taha AS, McCloskey C et al (2009) Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374(9684):119\u2013125","journal-title":"Lancet"},{"issue":"37","key":"124_CR37","first-page":"2094","volume":"175","author":"M Wurtz","year":"2013","unstructured":"Wurtz M, Grove EL (2013) Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions. Ugeskr Laeger 175(37):2094\u20132098","journal-title":"Ugeskr Laeger"},{"issue":"3","key":"124_CR38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)11878-8","volume":"119","author":"PA Shore","year":"1957","unstructured":"Shore PA, Brodie BB et al (1957) The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 119(3):361\u2013369","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"124_CR39","first-page":"591","volume":"98","author":"D Hollander","year":"1981","unstructured":"Hollander D, Dadufalza VD et al (1981) Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med 98(4):591\u2013598","journal-title":"J Lab Clin Med"},{"issue":"5","key":"124_CR40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2036.1997.00216.x","volume":"11","author":"MN Giraud","year":"1997","unstructured":"Giraud MN, Sanduja SK et al (1997) Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther 11(5):899\u2013906","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"124_CR41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2011.04707.x","volume":"34","author":"SD Saini","year":"2011","unstructured":"Saini SD, Fendrick AM et al (2011) Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 34(2):243\u2013251","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"124_CR42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5414\/CPP47564","volume":"47","author":"M Niazi","year":"2009","unstructured":"Niazi M, Andersson T et al (2009) Evaluation of the pharmacokinetic interaction between esomeprazole (40\u00a0mg) and acetylsalicylic acid (325\u00a0mg) in healthy volunteers. Int J Clin Pharmacol Ther 47(9):564\u2013569","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"124_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5414\/CP201400","volume":"49","author":"M Niazi","year":"2011","unstructured":"Niazi M, Andersson T et al (2011) Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40\u00a0mg and acetylsalicylic acid 325\u00a0mg and the monotherapies given separately in healthy volunteers. Int J Clin Pharmacol Ther 49(2):169\u2013176","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"124_CR44","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.clinthera.2011.10.009","volume":"33","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Hwang C et al (2011) Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. Clin Ther 33(12):1883\u20131893","journal-title":"Clin Ther"},{"key":"124_CR45","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","volume":"342","author":"M Charlot","year":"2011","unstructured":"Charlot M, Grove EL et al (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342:d2690","journal-title":"BMJ"},{"issue":"1","key":"124_CR46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1160\/TH13-07-0542","volume":"111","author":"LA Garcia Rodriguez","year":"2014","unstructured":"Garcia Rodriguez LA, Johansson S et al (2014) Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thromb Haemost 111(1):131\u2013139","journal-title":"Thromb Haemost"},{"issue":"1","key":"124_CR47","doi-asserted-by":"crossref","first-page":"e004564","DOI":"10.1161\/JAHA.112.004564","volume":"2","author":"SP Dunn","year":"2013","unstructured":"Dunn SP, Steinhubl SR et al (2013) Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2(1):e004564","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"124_CR48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ahj.2014.05.017","volume":"168","author":"DJ Whellan","year":"2014","unstructured":"Whellan DJ, Goldstein JL et al (2014) PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325\u00a0mg and immediate-release omeprazole 40\u00a0mg) versus enteric-coated aspirin 325\u00a0mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J 168(4):495\u2013502","journal-title":"Am Heart J"},{"issue":"3","key":"124_CR49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/003655200750024083","volume":"35","author":"P Inarrea","year":"2000","unstructured":"Inarrea P, Esteva F et al (2000) Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 35(3):242\u2013246","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"124_CR50","first-page":"535","volume":"16","author":"M Kasprzak","year":"2009","unstructured":"Kasprzak M, Kozinski M et al (2009) Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 16(6):535\u2013544","journal-title":"Cardiol J"},{"issue":"2","key":"124_CR51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/FJC.0b013e3181af6d9c","volume":"54","author":"AB Adamopoulos","year":"2009","unstructured":"Adamopoulos AB, Sakizlis GN et al (2009) Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol 54(2):163\u2013168","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"124_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","volume":"96","author":"M Wurtz","year":"2010","unstructured":"Wurtz M, Grove EL et al (2010) The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96(5):368\u2013371","journal-title":"Heart"},{"issue":"4","key":"124_CR53","first-page":"217","volume":"12","author":"T Andersson","year":"2012","unstructured":"Andersson T, Morrison D et al (2012) Evaluation of the pharmacodynamics of acetylsalicylic acid 81\u00a0mg with or without esomeprazole 20\u00a0mg in healthy volunteers. Am J Cardiovasc Drugs 12(4):217\u2013224","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"124_CR54","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0016-5085(96)70066-5","volume":"111","author":"LM Lichtenberger","year":"1996","unstructured":"Lichtenberger LM, Ulloa C et al (1996) Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 111(4):990\u2013995","journal-title":"Gastroenterology"},{"key":"124_CR55","unstructured":"Anand BS, Sanduja SK et al (1999) Effect of omeprazole on the bioavailability on aspirin: a randomized controlled study on healthy subjects [abstract]. Gastroenterology 35(3):116(4)\u2013A371"},{"issue":"10","key":"124_CR56","first-page":"549","volume":"36","author":"FZ Nefesoglu","year":"1998","unstructured":"Nefesoglu FZ, Ayanoglu-Dulger G et al (1998) Interaction of omeprazole with enteric-coated salicylate tablets. Int J Clin Pharmacol Ther 36(10):549\u2013553","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"124_CR57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/fca.13.67","volume":"9","author":"KP Bliden","year":"2013","unstructured":"Bliden KP, Brener M et al (2013) PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Future Cardiol 9(6):785\u2013797","journal-title":"Future Cardiol"},{"issue":"1","key":"124_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","volume":"152","author":"JJ Sung","year":"2010","unstructured":"Sung JJ, Lau JY et al (2010) Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 152(1):1\u20139","journal-title":"Ann Intern Med"},{"issue":"11","key":"124_CR59","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","volume":"4","author":"M Gilard","year":"2006","unstructured":"Gilard M, Arnaud B et al (2006) Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4(11):2508\u20132509","journal-title":"J Thromb Haemost"},{"issue":"33","key":"124_CR60","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.2174\/138161212803251862","volume":"18","author":"EL Grove","year":"2012","unstructured":"Grove EL, Storey RF et al (2012) Platelet function testing in atherothrombotic disease. Curr Pharm Des 18(33):5379\u20135391","journal-title":"Curr Pharm Des"},{"issue":"3","key":"124_CR61","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","volume":"51","author":"M Gilard","year":"2008","unstructured":"Gilard M, Arnaud B et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51(3):256\u2013260","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"124_CR62","doi-asserted-by":"crossref","first-page":"148e1","DOI":"10.1016\/j.ahj.2008.09.017","volume":"157","author":"JM Siller-Matula","year":"2009","unstructured":"Siller-Matula JM, Spiel AO et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157(1):148e1\u2013e5","journal-title":"Am Heart J"},{"issue":"4","key":"124_CR63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","volume":"48","author":"DS Small","year":"2008","unstructured":"Small DS, Farid NA et al (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48(4):475\u2013484","journal-title":"J Clin Pharmacol"},{"issue":"9694","key":"124_CR64","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue ML, Braunwald E et al (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694):989\u2013997","journal-title":"Lancet"},{"issue":"4","key":"124_CR65","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","volume":"101","author":"D Sibbing","year":"2009","unstructured":"Sibbing D, Morath T et al (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101(4):714\u2013719","journal-title":"Thromb Haemost"},{"issue":"13","key":"124_CR66","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","volume":"54","author":"T Cuisset","year":"2009","unstructured":"Cuisset T, Frere C et al (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54(13):1149\u20131153","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"124_CR67","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.thromres.2009.08.016","volume":"125","author":"CS Zuern","year":"2010","unstructured":"Zuern CS, Geisler T et al (2010) Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 125(2):e51\u2013e54","journal-title":"Thromb Res"},{"issue":"5","key":"124_CR68","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MEG.0b013e3283460110","volume":"23","author":"R Fontes-Carvalho","year":"2011","unstructured":"Fontes-Carvalho R, Albuquerque A et al (2011) Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 23(5):396\u2013404","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"124_CR69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","volume":"89","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Gibson CM et al (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89(1):65\u201374","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"124_CR70","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","volume":"14","author":"CA Stedman","year":"2000","unstructured":"Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14(8):963\u2013978","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"124_CR71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2044.2008.05861.x","volume":"64","author":"K Clark","year":"2009","unstructured":"Clark K, Lam LT et al (2009) The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia 64(6):652\u2013657","journal-title":"Anaesthesia"},{"issue":"11","key":"124_CR72","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0149-2918(00)83025-8","volume":"22","author":"PW Jungnickel","year":"2000","unstructured":"Jungnickel PW (2000) Pantoprazole: a new proton pump inhibitor. Clin Ther 22(11):1268\u20131293","journal-title":"Clin Ther"},{"issue":"5","key":"124_CR73","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.ijcard.2012.05.080","volume":"167","author":"MS Parri","year":"2013","unstructured":"Parri MS, Gianetti J et al (2013) Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol 167(5):2177\u20132181","journal-title":"Int J Cardiol"},{"issue":"7","key":"124_CR74","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/00498254.2011.653655","volume":"42","author":"M Ohbuchi","year":"2012","unstructured":"Ohbuchi M, Noguchi K et al (2012) Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica 42(7):633\u2013640","journal-title":"Xenobiotica"},{"issue":"3","key":"124_CR75","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2010.03717.x","volume":"70","author":"T Furuta","year":"2010","unstructured":"Furuta T, Iwaki T et al (2010) Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 70(3):383\u2013392","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"124_CR76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2014.28","volume":"15","author":"JP Depta","year":"2015","unstructured":"Depta JP, Lenzini PA et al (2015) Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 15(1):20\u201325","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"124_CR77","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1538-7836.2009.03729.x","volume":"8","author":"JS Hulot","year":"2010","unstructured":"Hulot JS, Wuerzner G et al (2010) Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 8(3):610\u2013613","journal-title":"J Thromb Haemost"},{"issue":"8","key":"124_CR78","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1538-7836.2011.04414.x","volume":"9","author":"H Fernando","year":"2011","unstructured":"Fernando H, Bassler N et al (2011) Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 9(8):1582\u20131589","journal-title":"J Thromb Haemost"},{"issue":"11","key":"124_CR79","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/gtmb.2012.0119","volume":"16","author":"Q Liu","year":"2012","unstructured":"Liu Q, Dang DS et al (2012) The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles. Genet Test Mol Biomarkers 16(11):1293\u20131297","journal-title":"Genet Test Mol Biomarkers"},{"issue":"20","key":"124_CR80","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363(20):1909\u20131917","journal-title":"N Engl J Med"},{"issue":"12","key":"124_CR81","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2008.05.053","volume":"52","author":"E Pezalla","year":"2008","unstructured":"Pezalla E, Day D et al (2008) Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 52(12):1038\u20131039","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"124_CR82","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","volume":"120","author":"JA Rassen","year":"2009","unstructured":"Rassen JA, Choudhry NK et al (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23):2322\u20132329","journal-title":"Circulation"},{"issue":"8","key":"124_CR83","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1592\/phco.30.8.787","volume":"30","author":"RP Kreutz","year":"2010","unstructured":"Kreutz RP, Stanek EJ et al (2010) Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 30(8):787\u2013796","journal-title":"Pharmacotherapy"},{"issue":"7","key":"124_CR84","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","volume":"180","author":"DN Juurlink","year":"2009","unstructured":"Juurlink DN, Gomes T et al (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7):713\u2013718","journal-title":"CMAJ"},{"issue":"9","key":"124_CR85","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","volume":"301","author":"PM Ho","year":"2009","unstructured":"Ho PM, Maddox TM et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937\u2013944","journal-title":"JAMA"},{"issue":"6","key":"124_CR86","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.amjcard.2009.10.063","volume":"105","author":"MA Gaglia Jr","year":"2010","unstructured":"Gaglia MA Jr, Torguson R et al (2010) Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 105(6):833\u2013838","journal-title":"Am J Cardiol"},{"issue":"9","key":"124_CR87","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/j.1875-9114.2012.01112.x","volume":"32","author":"SM Bhurke","year":"2012","unstructured":"Bhurke SM, Martin BC et al (2012) Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 32(9):809\u2013818","journal-title":"Pharmacotherapy"},{"issue":"3","key":"124_CR88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2796.2011.02423.x","volume":"271","author":"T Burkard","year":"2012","unstructured":"Burkard T, Kaiser CA et al (2012) Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 271(3):257\u2013263","journal-title":"J Intern Med"},{"issue":"6","key":"124_CR89","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","volume":"153","author":"M Charlot","year":"2010","unstructured":"Charlot M, Ahlehoff O et al (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153(6):378\u2013386","journal-title":"Ann Intern Med"},{"issue":"3","key":"124_CR90","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","volume":"167","author":"CS Kwok","year":"2013","unstructured":"Kwok CS, Jeevanantham V et al (2013) No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 167(3):965\u2013974","journal-title":"Int J Cardiol"},{"issue":"1","key":"124_CR91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2036.2010.04485.x","volume":"33","author":"VE Valkhoff","year":"2011","unstructured":"Valkhoff VE, \u2019t Jong GW et al (2011) Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 33(1):77\u201388","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"124_CR92","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2036.2011.04890.x","volume":"35","author":"M Schmidt","year":"2012","unstructured":"Schmidt M, Johansen MB et al (2012) Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 35(1):165\u2013174","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR93","doi-asserted-by":"crossref","first-page":"e4388","DOI":"10.1136\/bmj.e4388","volume":"345","author":"IJ Douglas","year":"2012","unstructured":"Douglas IJ, Evans SJ et al (2012) Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 345:e4388","journal-title":"BMJ"},{"issue":"8","key":"124_CR94","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","volume":"125","author":"SG Goodman","year":"2012","unstructured":"Goodman SG, Clare R et al (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO. Circulation 125(8):978\u2013986","journal-title":"Circulation"},{"issue":"3","key":"124_CR95","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11239-008-0282-2","volume":"28","author":"QP Gao","year":"2009","unstructured":"Gao QP, Sun Y et al (2009) Early use of omeprazole benefits patients with acute myocardial infarction. J Thromb Thrombolysis 28(3):282\u2013287","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"124_CR96","first-page":"856","volume":"124","author":"YH Ren","year":"2011","unstructured":"Ren YH, Zhao M et al (2011) Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl) 124(6):856\u2013861","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"124_CR97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1013859","volume":"364","author":"DN Juurlink","year":"2011","unstructured":"Juurlink DN (2011) Clopidogrel with or without omeprazole in coronary disease. N Engl J Med 364(7):681\u2013682","journal-title":"N Engl J Med"},{"issue":"6","key":"124_CR98","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/clpt.2011.201","volume":"90","author":"PA Gurbel","year":"2011","unstructured":"Gurbel PA, Bliden KP et al (2011) Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 with Clopidogrel Interaction Gauging (SPACING) study. Clin Pharmacol Ther 90(6):860\u2013866","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"124_CR99","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.110.957829","volume":"3","author":"JL Ferreiro","year":"2010","unstructured":"Ferreiro JL, Ueno M et al (2010) Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv 3(5):436\u2013441","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"124_CR100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCOUTCOMES.114.001177","volume":"8","author":"C Melloni","year":"2015","unstructured":"Melloni C, Washam JB et al (2015) Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes 8(1):47\u201355","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"124_CR101","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCOUTCOMES.114.001586","volume":"8","author":"PB Berger","year":"2015","unstructured":"Berger PB (2015) Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn! Circ Cardiovasc Qual Outcomes 8(1):6\u20137","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"124_CR102","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH11-09-0622","volume":"107","author":"D Aradi","year":"2012","unstructured":"Aradi D, Kuliczkowski W et al (2012) Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 107(2):338\u2013345","journal-title":"Thromb Haemost"},{"issue":"15","key":"124_CR103","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","volume":"32","author":"PG Steg","year":"2011","unstructured":"Steg PG, Huber K et al (2011) Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 32(15):1854\u20131864","journal-title":"Eur Heart J"},{"issue":"9748","key":"124_CR104","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","volume":"376","author":"SR Mehta","year":"2010","unstructured":"Mehta SR, Tanguay JF et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748):1233\u20131243","journal-title":"Lancet"},{"issue":"9038","key":"124_CR105","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329\u20131339","journal-title":"Lancet"},{"key":"124_CR106","doi-asserted-by":"crossref","first-page":"d4094","DOI":"10.1136\/bmj.d4094","volume":"343","author":"LA Garcia Rodriguez","year":"2011","unstructured":"Garcia Rodriguez LA, Cea-Soriano L et al (2011) Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 343:d4094","journal-title":"BMJ"},{"issue":"2","key":"124_CR107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amjcard.2010.08.067","volume":"107","author":"R Rossini","year":"2011","unstructured":"Rossini R, Capodanno D et al (2011) Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 107(2):186\u2013194","journal-title":"Am J Cardiol"},{"issue":"12","key":"124_CR108","first-page":"935","volume":"82","author":"J Connor","year":"2004","unstructured":"Connor J, Rafter N et al (2004) Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 82(12):935\u2013939","journal-title":"Bull World Health Organ"},{"key":"124_CR109","first-page":"419","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A et al (2013) Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 7:419\u2013434","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"124_CR110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad S et al (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55(2):399\u2013407","journal-title":"Hypertension"},{"issue":"8","key":"124_CR111","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/heartjnl-2012-302371","volume":"99","author":"JJ Focks","year":"2013","unstructured":"Focks JJ, Brouwer MA et al (2013) Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart 99(8):520\u2013527","journal-title":"Heart"},{"issue":"9","key":"124_CR112","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/jth.12318","volume":"11","author":"M Wurtz","year":"2013","unstructured":"Wurtz M, Lordkipanidze M et al (2013) Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost 11(9):1627\u20131639","journal-title":"J Thromb Haemost"},{"issue":"9","key":"124_CR113","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/17425255.2012.711318","volume":"8","author":"M Wurtz","year":"2012","unstructured":"Wurtz M, Grove EL (2012) Combining aspirin and proton pump inhibitors: for whom the warning bell tolls? Expert Opin Drug Metab Toxicol 8(9):1051\u20131055","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"124_CR114","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","volume":"8","author":"JM Siller-Matula","year":"2010","unstructured":"Siller-Matula JM, Jilma B et al (2010) Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 8(12):2624\u20132641","journal-title":"J Thromb Haemost"}],"container-title":["Advances in Experimental Medicine and Biology","Thrombosis and Embolism: from Research to Clinical Practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2016_124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:17:47Z","timestamp":1749557867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2016_124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319221076","9783319221083"],"references-count":114,"URL":"https:\/\/doi.org\/10.1007\/5584_2016_124","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}